 |
|||||
 |
 |
 |
 |
 |
 |
 |
|||||
|
||||||||||||||||||
| TARGA DRUG DEVELOPMENT AND BUSINESS TEAM
Dr. Rosenblum
heads M. D. Anderson Cancer Center’s Section of Immunopharmacology
and Targeted Therapy (ITT) 10 member-laboratory with expertise in the
pre-clinical and clinical development of numerous agents, some of which
have been approved utilizing the laboratory’s own clinical trial
data. ITT's training and expertise in the area of Pharmacology/Toxicology
ranges from pre-clinical developmental stages (cellular pharmacology,
animal pharmacology and toxicology studies) through Phase I and II clinical
trial design, clinical pharmacology design, pharmacokinetic analysis and
data interpretation.
Dr. Howell
is a medical oncologist and Professor of Medicine at the University of
California, San Diego where he directs the Cancer Pharmacology Program
of the Cancer Center and runs a laboratory-based research program focused
on mechanisms of drug resistance. This Program is responsible for the
development and testing of new chemotherapeutic agents and therapeutic
strategies. Dr. Howell was responsible for co-inventing the DepoFoam™
drug-delivery technology and developing DepoCyte™, the first product
based on this technology, all the way through NDA approval. Dr. Howell
serves as co-Chairman of the GYN Committee of the Southwest Oncology Group
and has extensive experience in the design, development, and execution
of cancer clinical trials. He serves on the scientific advisory boards
of several pharmaceutical companies, and is a Director of Access Pharmaceutics.
In a prior
position as president of DepoTech Corp., Mr. Aronson had overall responsibility
for supervising the pre-clinical and clinical development of several new
sustained-release formulations in a number of therapeutic fields, including
DepoCyte™, an anti-cancer drug now on the market, DepoMorphine™
a pain medication whose NDA has now been submitted for U.S. FDA approval
and DepoBupivacaine™, a pain medications currently in advanced human
clinical trials, and several other formulations in various stages of development.
Working as a corporate and securities attorney with Brobeck, Phleger & Harrison in Palo Alto, California, Dr. Meisel assisted numerous biotech companies, venture capitalists and underwriters in the start-up phase of newly formed businesses, private and public financings, initial public offerings, mergers and acquisitions, and licensing and technology transfers. Dr. Meisel formerly served on the board of directors of CPS Chemical Company. As vice president of operations at CPS, Dr. Meisel was co-inventor of chemical processing techniques and compositions of matter covered by several patents, supervisor of legal, research and manufacturing operations, and part of the executive management team that sold the company to Allied Colloids, plc in England. Dr. Meisel is currently on the board of directors of the International Association of CFS/ME and previously was a founding board member and vice president of the HHV-6 Foundation. As president and director of Windsor Bay Capital, Inc. in Boca Raton, Florida and managing member of Orion Capital Group, LLC, Dr. Meisel is an experienced biotech investor. Dr. Meisel currently also serves on the board of directors and scientific advisory board of Epiphany BioSciences, Inc.
Clinical
Advisory Board/Consultants
Jeffrey
S. Weber, M.D., Ph.D. |
ABOUT US: Markets | Corperate Strategy | Team | News HOME - TECHNOLOGIES - PRODUCT CANDIDATES - SERVICES - ABOUT US - CONTACT |
A
graduate of New Jersey Medical School, Dr. Meisel went on to receive an
M.P.H. degree at Harvard School of Public Health and to complete his residency
and fellowship in anesthesiology and critical care medicine at Brigham
& Women’s Hospital, Harvard Medical School. After working as
Chief of Anesthesia at Kaiser Permanente Medical Center in San Francisco
and as a private practice anesthesiologist in San Jose, California, Dr.
Meisel received his J.D. from Stanford Law School.
S.
Gail Eckhardt, M.D.